JP2017510564A5 - - Google Patents

Download PDF

Info

Publication number: JP2017510564A5
Authority: JP; Japan
Prior art keywords: carboxamide; cyclohexyl; bibenzimidazolyl; alkyl; ethyl
Prior art date: 2015-02-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2016554419A

Other languages

English (en)

Japanese (ja)

Other versions

JP2017510564A (ja

Filing date

2015-02-24

Publication date

2018-03-08

2014-02-27 Priority claimed from EP14305285.0A external-priority patent/EP2913330A1/en

2015-02-24 Application filed filed Critical

2017-04-13 Publication of JP2017510564A publication Critical patent/JP2017510564A/ja

2018-03-08 Publication of JP2017510564A5 publication Critical patent/JP2017510564A5/ja

Status Pending legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 description 24
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 20
-1 1-cyclohexyl-1H-benzimidazol-5-yl Chemical group 0.000 description 20
125000000623 heterocyclic group Chemical group 0.000 description 17
125000001424 substituent group Chemical group 0.000 description 15
125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 12
150000003839 salts Chemical class 0.000 description 12
239000002253 acid Substances 0.000 description 11
125000000753 cycloalkyl group Chemical group 0.000 description 11
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 11
125000000217 alkyl group Chemical group 0.000 description 10
229910052799 carbon Inorganic materials 0.000 description 9
125000002950 monocyclic group Chemical group 0.000 description 9
229910052760 oxygen Inorganic materials 0.000 description 9
230000000844 anti-bacterial effect Effects 0.000 description 8
229940088710 antibiotic agent Drugs 0.000 description 8
125000005843 halogen group Chemical group 0.000 description 8
125000005842 heteroatom Chemical group 0.000 description 8
229910052717 sulfur Inorganic materials 0.000 description 8
125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 7
229920006395 saturated elastomer Polymers 0.000 description 7
125000002619 bicyclic group Chemical group 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 5
239000003814 drug Substances 0.000 description 5
239000000203 mixture Substances 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 4
125000003635 2-dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 3
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 3
125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 3
241000192125 Firmicutes Species 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
125000003710 aryl alkyl group Chemical group 0.000 description 3
150000001721 carbon Chemical group 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
244000000010 microbial pathogen Species 0.000 description 3
125000004433 nitrogen atom Chemical group N* 0.000 description 3
230000002265 prevention Effects 0.000 description 3
DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 2
125000006528 (C2-C6) alkyl group Chemical group 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
108010015899 Glycopeptides Proteins 0.000 description 2
102000002068 Glycopeptides Human genes 0.000 description 2
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
108010028921 Lipopeptides Proteins 0.000 description 2
241000194017 Streptococcus Species 0.000 description 2
125000000304 alkynyl group Chemical group 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000001775 anti-pathogenic effect Effects 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
210000002421 cell wall Anatomy 0.000 description 2
125000000392 cycloalkenyl group Chemical group 0.000 description 2
230000002519 immonomodulatory effect Effects 0.000 description 2
230000015788 innate immune response Effects 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
125000000719 pyrrolidinyl group Chemical group 0.000 description 2
230000008685 targeting Effects 0.000 description 2
MYLFPYVBTQNYNC-VGSWGCGISA-N (3R,4R)-1-[7-(1-cyclohexylbenzimidazol-5-yl)-1H-imidazo[4,5-b]pyridin-5-yl]-4-(hydroxymethyl)piperidin-3-ol Chemical compound C1(CCCCC1)N1C=NC2=C1C=CC(=C2)C2=C1C(=NC(=C2)N2C[C@@H]([C@H](CC2)CO)O)NC=N1 MYLFPYVBTQNYNC-VGSWGCGISA-N 0.000 description 1
HMLNROFPENVPSM-UHFFFAOYSA-N 2-[[7-(1-cyclohexylbenzimidazol-5-yl)-1H-imidazo[4,5-b]pyridin-5-yl]amino]ethanol Chemical compound C1(CCCCC1)N1C=NC2=C1C=CC(=C2)C2=C1C(=NC(=C2)NCCO)NC=N1 HMLNROFPENVPSM-UHFFFAOYSA-N 0.000 description 1
NGGZPLMLAYBHRK-UHFFFAOYSA-N 4-(1-cyclohexylbenzimidazol-5-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide Chemical compound C1(CCCCC1)N1C=NC2=C1C=CC(=C2)C2=NC=C(C1=C2N=CN1)C(=O)N NGGZPLMLAYBHRK-UHFFFAOYSA-N 0.000 description 1
125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
DEDSYSQKGKSRLV-UHFFFAOYSA-N 5-(2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-5-yl)-7-(1-cyclohexylbenzimidazol-5-yl)-1H-imidazo[4,5-b]pyridine Chemical compound C1(CCCCC1)N1C=NC2=C1C=CC(=C2)C2=C1C(=NC(=C2)N2CC3CNCC3C2)NC=N1 DEDSYSQKGKSRLV-UHFFFAOYSA-N 0.000 description 1
PXVXDVDJIJEKKA-UHFFFAOYSA-N 5-[2-(dimethylamino)ethyl-methylamino]-7-(1-ethyl-2-oxopyridin-4-yl)-3H-benzimidazole-4-carboxamide Chemical compound CN(CCN(C1=C(C2=C(N=CN2)C(=C1)C1=CC(N(C=C1)CC)=O)C(=O)N)C)C PXVXDVDJIJEKKA-UHFFFAOYSA-N 0.000 description 1
GBCRUYLURFQWBO-UHFFFAOYSA-N 5-[2-(dimethylamino)ethyl-methylamino]-7-(9-oxa-1,3-diazatricyclo[6.3.1.04,12]dodeca-2,4(12),5,7-tetraen-6-yl)-3H-benzimidazole-4-carboxamide Chemical compound N1=CN2CCOC3=CC(=CC1=C23)C2=CC(=C(C3=C2N=CN3)C(=O)N)N(C)CCN(C)C GBCRUYLURFQWBO-UHFFFAOYSA-N 0.000 description 1
VPCRDEHPHHOPII-UHFFFAOYSA-N 5-[2-(dimethylamino)ethyl-methylamino]-7-quinolin-7-yl-3H-benzimidazole-4-carboxamide Chemical compound CN(CCN(C1=C(C2=C(N=CN2)C(=C1)C1=CC=C2C=CC=NC2=C1)C(=O)N)C)C VPCRDEHPHHOPII-UHFFFAOYSA-N 0.000 description 1
IJRYAAARUAZFRM-UHFFFAOYSA-N 7-(3,4-dihydro-2H-pyrano[2,3-b]pyridin-6-yl)-5-[2-(dimethylamino)ethoxy]-3H-benzimidazole-4-carboxamide Chemical compound O1CCCC=2C1=NC=C(C2)C2=CC(=C(C1=C2N=CN1)C(=O)N)OCCN(C)C IJRYAAARUAZFRM-UHFFFAOYSA-N 0.000 description 1
BQIJIBLZNXVMGV-UHFFFAOYSA-N 7-(3,4-dihydro-2H-pyrano[2,3-b]pyridin-6-yl)-5-[2-(dimethylamino)ethyl-methylamino]-3H-benzimidazole-4-carboxamide Chemical compound O1CCCC=2C1=NC=C(C2)C2=CC(=C(C1=C2N=CN1)C(=O)N)N(C)CCN(C)C BQIJIBLZNXVMGV-UHFFFAOYSA-N 0.000 description 1
FBCCTOXLYHBZFI-UHFFFAOYSA-N 7-(3,4-dihydro-2H-pyrano[2,3-b]pyridin-6-yl)-5-[methyl(2-pyrrolidin-1-ylethyl)amino]-3H-benzimidazole-4-carboxamide Chemical compound O1CCCC=2C1=NC=C(C2)C2=CC(=C(C1=C2N=CN1)C(=O)N)N(CCN1CCCC1)C FBCCTOXLYHBZFI-UHFFFAOYSA-N 0.000 description 1
BUEWHORURWJKBU-UHFFFAOYSA-N 7-(3-carbamoyl-4-methoxyphenyl)-5-[2-(dimethylamino)ethyl-methylamino]-3H-benzimidazole-4-carboxamide Chemical compound C(N)(=O)C=1C=C(C=CC1OC)C1=CC(=C(C2=C1N=CN2)C(=O)N)N(C)CCN(C)C BUEWHORURWJKBU-UHFFFAOYSA-N 0.000 description 1
UGDNDOCUZFCATI-UHFFFAOYSA-N C1(CC1)C=1C=C(C=NC=1)C1=CC(=C(C=2NC=NC=21)C(=O)N)N(C)CCN(C)C Chemical compound C1(CC1)C=1C=C(C=NC=1)C1=CC(=C(C=2NC=NC=21)C(=O)N)N(C)CCN(C)C UGDNDOCUZFCATI-UHFFFAOYSA-N 0.000 description 1
DPFVLNXOYPRINQ-UHFFFAOYSA-N C1=NC2=C(N1C1CCCCC1)C=CC(C1=C3N=CNC3=C(C(F)(F)F)C(N3CCC(CC3)CO)=C1)=C2 Chemical compound C1=NC2=C(N1C1CCCCC1)C=CC(C1=C3N=CNC3=C(C(F)(F)F)C(N3CCC(CC3)CO)=C1)=C2 DPFVLNXOYPRINQ-UHFFFAOYSA-N 0.000 description 1
125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
LDZCAHZVXGPGBL-UHFFFAOYSA-N CN(CCN(C1=C(C2=C(C(=N1)C1=CC3=C(N(C=N3)CC)C=C1)N=CN2)C(=O)N)C)C Chemical compound CN(CCN(C1=C(C2=C(C(=N1)C1=CC3=C(N(C=N3)CC)C=C1)N=CN2)C(=O)N)C)C LDZCAHZVXGPGBL-UHFFFAOYSA-N 0.000 description 1
RVEDVHRGUBDXEH-UHFFFAOYSA-N CN(CCN(C1=C(C2=C(N=CN2)C(=C1)C1=CC2=C(N(C=N2)C2=CC=CC=C2)C=C1)C(=O)N)C)C Chemical compound CN(CCN(C1=C(C2=C(N=CN2)C(=C1)C1=CC2=C(N(C=N2)C2=CC=CC=C2)C=C1)C(=O)N)C)C RVEDVHRGUBDXEH-UHFFFAOYSA-N 0.000 description 1
LQSXOZDBYGXRQD-UHFFFAOYSA-N CN(CCN(C1=C(C2=C(N=CN2)C(=C1)C=1C=NC(=CC=1)N(C)C)C(=O)N)C)C Chemical compound CN(CCN(C1=C(C2=C(N=CN2)C(=C1)C=1C=NC(=CC=1)N(C)C)C(=O)N)C)C LQSXOZDBYGXRQD-UHFFFAOYSA-N 0.000 description 1
ZIGLWSRPWRLDTR-UHFFFAOYSA-N CN(CCN(C1=C(C2=C(N=CN2)C(=C1)C=1C=NC=C(C1)N1CCCC1)C(=O)N)C)C Chemical compound CN(CCN(C1=C(C2=C(N=CN2)C(=C1)C=1C=NC=C(C1)N1CCCC1)C(=O)N)C)C ZIGLWSRPWRLDTR-UHFFFAOYSA-N 0.000 description 1
ZNMKIJKDWSNECL-QNSVNVJESA-N CN1[C@H](CCC1)COC1=C(C2=C(N=CN2)C(=C1)C1=CC2=C(N(C=N2)C2COCCC2)C=C1)C(=O)N Chemical compound CN1[C@H](CCC1)COC1=C(C2=C(N=CN2)C(=C1)C1=CC2=C(N(C=N2)C2COCCC2)C=C1)C(=O)N ZNMKIJKDWSNECL-QNSVNVJESA-N 0.000 description 1
241000194032 Enterococcus faecalis Species 0.000 description 1
241000194031 Enterococcus faecium Species 0.000 description 1
101001110286 Homo sapiens Ras-related C3 botulinum toxin substrate 1 Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
RAIVFRRGCHJKBV-YVWKXTFCSA-N NC(=O)C1=C(OC[C@H]2CCCN2)C=C(C2=C1NC=N2)C1=CC=C2N(C=NC2=C1)[C@@H]1CCCC[C@H]1F Chemical compound NC(=O)C1=C(OC[C@H]2CCCN2)C=C(C2=C1NC=N2)C1=CC=C2N(C=NC2=C1)[C@@H]1CCCC[C@H]1F RAIVFRRGCHJKBV-YVWKXTFCSA-N 0.000 description 1
HNLSHAHMWRQASX-UHFFFAOYSA-N O1CCCC=2C1=NC=C(C2)C2=CC(=C(C1=C2N=CN1)C(=O)N)N1CC(CCC1)N(C)C Chemical compound O1CCCC=2C1=NC=C(C2)C2=CC(=C(C1=C2N=CN1)C(=O)N)N1CC(CCC1)N(C)C HNLSHAHMWRQASX-UHFFFAOYSA-N 0.000 description 1
GRNYXVHDNJVYFL-UHFFFAOYSA-N O1CCCC=2C1=NC=C(C2)C2=CC(=C(C1=C2N=CN1)C(=O)N)OC1CN(CCC1)C Chemical compound O1CCCC=2C1=NC=C(C2)C2=CC(=C(C1=C2N=CN1)C(=O)N)OC1CN(CCC1)C GRNYXVHDNJVYFL-UHFFFAOYSA-N 0.000 description 1
DEGIASFEDQNETG-UHFFFAOYSA-N O1CCCC=2C1=NC=C(C2)C2=CC(=C(C1=C2N=CN1)C(=O)N)OCC1N(CCC1)C Chemical compound O1CCCC=2C1=NC=C(C2)C2=CC(=C(C1=C2N=CN1)C(=O)N)OCC1N(CCC1)C DEGIASFEDQNETG-UHFFFAOYSA-N 0.000 description 1
DEGIASFEDQNETG-OAHLLOKOSA-N O1CCCC=2C1=NC=C(C2)C2=CC(=C(C1=C2N=CN1)C(=O)N)OC[C@@H]1N(CCC1)C Chemical compound O1CCCC=2C1=NC=C(C2)C2=CC(=C(C1=C2N=CN1)C(=O)N)OC[C@@H]1N(CCC1)C DEGIASFEDQNETG-OAHLLOKOSA-N 0.000 description 1
CYHIIJXAPLSUIC-UHFFFAOYSA-N OCC1(CCN(CC1)C1=C(C2=C(N=CN2)C(=C1)C1=CC2=C(N(C=N2)C2CCCCC2)C=C1)C(=O)N)CO Chemical compound OCC1(CCN(CC1)C1=C(C2=C(N=CN2)C(=C1)C1=CC2=C(N(C=N2)C2CCCCC2)C=C1)C(=O)N)CO CYHIIJXAPLSUIC-UHFFFAOYSA-N 0.000 description 1
102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 1
101100170580 Staphylococcus aureus dltA gene Proteins 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
229940032049 enterococcus faecalis Drugs 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
125000003367 polycyclic group Chemical group 0.000 description 1

JP2016554419A 2014-02-27 2015-02-24 新規なヘテロ芳香族誘導体およびそれらの医薬としての使用 Pending JP2017510564A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP14305285.0A EP2913330A1 (en)	2014-02-27	2014-02-27	Condensed derivatives of imidazole useful as pharmaceuticals
EP14305285.0		2014-02-27
PCT/EP2015/053857 WO2015128333A1 (en)	2014-02-27	2015-02-24	Heteroaromatic derivatives and their use as pharmaceuticals

Publications (2)

Publication Number	Publication Date
JP2017510564A JP2017510564A (ja)	2017-04-13
JP2017510564A5 true JP2017510564A5 (2)	2018-03-08

Family

ID=50231103

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2016554419A Pending JP2017510564A (ja)	2014-02-27	2015-02-24	新規なヘテロ芳香族誘導体およびそれらの医薬としての使用

Country Status (4)

Country	Link
US (1)	US10301305B2 (2)
EP (2)	EP2913330A1 (2)
JP (1)	JP2017510564A (2)
WO (1)	WO2015128333A1 (2)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3868752A1 (en)	2014-08-28	2021-08-25	Asceneuron SA	Glycosidase inhibitors
CN108689945A (zh) *	2015-12-01	2018-10-23	江苏理工学院	一种苯并咪唑衍生物的制备方法
SG11201807012QA (en)	2016-02-25	2018-09-27	Asceneuron S A	Acid addition salts of piperazine derivatives
AU2017222958B2 (en)	2016-02-25	2019-07-18	Asceneuron S. A.	Glycosidase inhibitors
US11261183B2 (en)	2016-02-25	2022-03-01	Asceneuron Sa	Sulfoximine glycosidase inhibitors
CN108884078A (zh)	2016-02-25	2018-11-23	阿森纽荣股份公司	糖苷酶抑制剂
CN106588818B (zh) *	2016-11-30	2019-07-26	兰州大学	一种医药中间体2,6-二氟-3-吗啉苯基甲胺及其制备方法
WO2018154133A1 (en)	2017-02-27	2018-08-30	Janssen Pharmaceutica Nv	[1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors
US11207312B2 (en)	2017-07-17	2021-12-28	Merck Sharp & Dohme Corp.	Metallo-beta-lactamase inhibitors and methods of use thereof
WO2019037860A1 (en)	2017-08-24	2019-02-28	Asceneuron S.A.	LINEAR INHIBITORS OF GLYCOSIDASE
SG11202101255UA (en)	2018-08-09	2021-03-30	Antabio Sas	Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en)	2018-08-09	2024-02-20	Antabio Sas	Diazabicyclooctanones as inhibitors of serine beta-lactamases
IL280841B2 (en)	2018-08-22	2024-12-01	Asceneuron S A	Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors
WO2020039027A1 (en)	2018-08-22	2020-02-27	Asceneuron S. A.	Pyrrolidine glycosidase inhibitors
WO2020039029A1 (en)	2018-08-22	2020-02-27	Asceneuron S. A.	Spiro compounds as glycosidase inhibitors
WO2020039028A1 (en)	2018-08-22	2020-02-27	Asceneuron S. A.	Tetrahydro-benzoazepine glycosidase inhibitors
US11787775B2 (en) *	2020-07-24	2023-10-17	Genentech, Inc.	Therapeutic compounds and methods of use
WO2022166468A1 (zh) *	2021-02-03	2022-08-11	药雅科技(上海)有限公司	Bruton's酪氨酸激酶抑制剂及其应用
CN114957241B (zh) *	2021-02-23	2023-08-22	药雅科技(上海)有限公司	杂环类化合物作为激酶抑制剂的制备及其应用
EP4326713A4 (en) *	2021-04-12	2025-03-19	Impact Therapeutics (Shanghai), Inc.	Substituted fused bicyclic compounds as parp inhibitors and the use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS59126140A (ja)	1982-12-30	1984-07-20	Aisin Warner Ltd	車両用自動変速機のトランスミツシヨン
US5523408A (en)	1994-03-25	1996-06-04	The Dupont Merck Pharmaceutical Company	2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
CA2196792A1 (en)	1994-08-04	1996-02-15	Yoon T. Jeon	Novel benzimidazole derivatives
DK1474425T3 (da) *	2002-01-07	2006-09-25	Eisai Co Ltd	Deazapuriner og anvendelser deraf
AR042956A1 (es) *	2003-01-31	2005-07-13	Vertex Pharma	Inhibidores de girasa y usos de los mismos
JP5002851B2 (ja)	2005-01-20	2012-08-15	独立行政法人理化学研究所	イミダゾピリジン誘導体
US20060247263A1 (en)	2005-04-19	2006-11-02	Amgen Inc.	Substituted heterocyclic compounds and methods of use
US20080139608A1 (en) *	2006-12-06	2008-06-12	Universiteit Leiden	2,6,8, Trisubstituted 1-deazapurines and their different uses
JP2009046435A (ja)	2007-08-21	2009-03-05	Mitsubishi Tanabe Pharma Corp	グルココルチコイド受容体モジュレーター
GB2480816A (en) *	2010-06-01	2011-12-07	Summit Corp Plc	Compounds for the treatment of Clostridium difficile associated diseases
ES2803556T3 (es) *	2010-06-01	2021-01-27	Summit Oxford Ltd	Compuestos para el tratamiento de enfermedades asociadas a clostridium difficile
WO2012172043A1 (en)	2011-06-15	2012-12-20	Laboratoire Biodim	Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections
WO2014014845A1 (en) *	2012-07-18	2014-01-23	Vertex Pharmaceuticals Incorporated	Combination therapy comprising\|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-\|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium\|diseases
DE102013009415A1 (de) *	2013-06-05	2014-12-11	Man Diesel & Turbo Se	Kolben einer Brennkraftmaschine
JP6461118B2 (ja) *	2013-06-21	2019-01-30	ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈＥｐｉｇｅｎｅｔｉｃｓＬｔｄ．	ブロモドメイン阻害剤としての新規の置換された二環式化合物
SG10201908467RA (en)	2014-01-31	2019-10-30	Bristol Myers Squibb Co	Macrocycles with hetrocyclic p2' groups as factor xia inhibitors

2014
- 2014-02-27 EP EP14305285.0A patent/EP2913330A1/en not_active Withdrawn
2015
- 2015-02-24 EP EP15708148.0A patent/EP3110803B1/en not_active Not-in-force
- 2015-02-24 US US15/121,103 patent/US10301305B2/en not_active Expired - Fee Related
- 2015-02-24 WO PCT/EP2015/053857 patent/WO2015128333A1/en not_active Ceased
- 2015-02-24 JP JP2016554419A patent/JP2017510564A/ja active Pending

Publication	Publication Date	Title
JP2017510564A5 (2)	2018-03-08
AU2015296322B2 (en)	2019-09-19	2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
CN105294683B (zh)	2018-01-23	Cdk类小分子抑制剂的化合物及其用途
CA2732950C (en)	2013-10-01	Imidazopyridin-2-one derivatives
EP3875078A1 (en)	2021-09-08	Compounds for the treatment of covid-19
JP2015504057A5 (2)	2016-02-12
JP2015508075A5 (2)	2016-03-03
JP2019500352A5 (2)	2020-01-30
KR102148681B1 (ko)	2020-08-27	Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물
JP2018522034A5 (2)	2019-09-12
NZ628186A (en)	2016-03-31	Compounds for treating spinal muscular atrophy
JP2014513139A5 (2)	2015-06-25
JP2015511224A5 (2)	2016-03-03
EP2750678A1 (en)	2014-07-09	Antibacterial compounds and methods for use
HRP20110942T1 (hr)	2012-01-31	(dihidro)pirolo[2,1-a]izohinolini
JP2015500884A5 (2)	2016-02-18
JP2020526549A5 (2)	2021-08-19
JP2019504102A5 (2)	2020-03-12
CR20230008A (es)	2023-01-25	Metil (r)-2-(fluorometil)-5-oxo-4-fenil-4,5,6,7-tetrahidro-1h-ciclopenta[b]piridin-3-carboxilato y metil (r)-2-(fluorometil)-5-oxo-4-fenil-1,4,5,7-tetrahidrofuro[3,4-b]piridin-3-carboxilato como activadores de cav1.2
SI2864328T1 (en)	2018-04-30	Pharmaceutically active compounds
US20160251339A1 (en)	2016-09-01	Aromatic heterocyclic compounds and their application in pharmaceuticals
Domagala et al.	2003	Structure‐activity relationships of the quinolone antibacterials in the new millennium: some things change and some do not
WO2011096490A1 (ja)	2011-08-11	イミダゾピリジン－２－オン誘導体
RU2011126981A (ru)	2013-01-10	ПРОИЗВОДНЫЕ 6-ЦИКЛОАМИНО-3-(1Н-ПИРРОЛО[2,3-b]ПИРИДИН-4-ИЛ)ИМИДАЗО[1,2-b]ПИРИДАЗИНА, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ
JP2011178779A (ja)	2011-09-15	イミダゾピリジン−２−オン誘導体